Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

New Kid On The Block: Pfizer/Pharmacia Merger Points To Drug-Device Play

This article was originally published in The Gray Sheet

  • News

Executive Summary

Pfizer will leverage its acquisition of Pharmacia to carve out a combination drug-device business to support its needle-less insulin delivery initiatives

You may also be interested in...



Pharmacia Device/Diagnostics Unit Ripe For Picking, Pfizer Says

Pfizer's July 1 announcement that it will explore strategic options for divesting Pharmacia's device and diagnostics division confirms the company's intentions to shed non-core assets

Pharmacia Device/Diagnostics Unit Ripe For Picking, Pfizer Says

Pfizer's July 1 announcement that it will explore strategic options for divesting Pharmacia's device and diagnostics division confirms the company's intentions to shed non-core assets

Boston Scientific Leads The Charge For Stem Cell Alliances With Osiris Stake

Boston Scientific's investment in stem cell therapy developer Osiris Therapeutics may signal a wave of device/biotech collaborations related to delivery techniques for stem cell treatments

Table

View full table

Tags:
Latest Headlines

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation

Second EU MDR Notified Body Designated In France

Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217

See All
UsernamePublicRestriction

Register

MT018249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By